Jefferies Cuts Price Target on Regeneron (REGN) Following District Court Ruling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
January 5, 2017 8:00 PM ESTTARRYTOWN, N.Y. and PARIS, Jan. 5, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that they will appeal the injunction granted today by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent® in the U.S. during the term of two Amgen patents. The companies believe Amgen's asserted patent claims are invalid and will also appeal a prior jury verdict upholding the validity of those patents. The court has delayed imposition of the injunction for 30 days to allow Sanofi and Regeneron to file... More
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
January 4, 2017 7:00 AM ESTTARRYTOWN, N.Y., Jan. 4, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Jay Markowitz, M.D., has joined the company as Senior Vice President, Portfolio Management. Dr. Markowitz has 15 years of experience as a leading institutional investor and analyst in the biopharmaceutical sector. He was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager.
"Jay is a powerful addition to our leadership team at a very important time for the company as our pipeline continues to grow... More
